These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
With the Federal Reserve lifting interest rates for the first time in more than three years and signalling that money will not be cheap again quickly, investors are being pushed to think harder about where real growth could justify the risk. Biotech developers with fast-rising revenues but P/B ratios below sector norms offer one such angle. This article highlights three of the stocks that stand out most from that screener.
The three biotechs profiled below are only a small sample, since the full screen identified another 126 North American developers with similar revenue profiles and subsector P/B valuations that are not covered here.
If you want to move beyond this shortlist and start sizing up the wider opportunity set, head straight to the Fast-Growing North American Biotechs Trading Below Industry Price-to-Book screener to identify, analyze, and narrow in on the highest conviction ideas for your watchlist.
Optimi Health (OPTH)
Overview: Optimi Health is a Canadian pharmaceutical manufacturer producing MDMA, psilocybin, psilocin, and mushroom-based supplements for clinics, trials, and wellness markets.
Operations: The business currently reports about CA$0.18 million of revenue from farming, processing, and distributing agrifood-related mushroom products.
Market Cap: $29.5 million
Optimi Health fits this screener because it is already supplying regulated psychedelic medicines into real treatment settings, giving investors early exposure to commercial psychedelic therapeutics rather than just pipeline potential.
"Optimi’s MDMA shipments to Australian clinics have climbed in a clean staircase: 160 doses (Sept 2024) → 700 (Jan 2025) → 1,000 (April 2025) → 1,000 (Nov 2025) → 1,000 (Feb 2026). Those are repeat orders, the clearest signal that clinics are using the product and coming back for more."
What ultimately matters is how one underappreciated capacity decision filters through to margins once demand and reimbursement catch up to the factory.
The most followed narrative for Optimi Health discusses its potential mispricing. It points out how Optimi Health is not a clinical-stage pharma company, but it appears to be valued like one. Instead, Optimi has real orders and is generating real revenue. It highlights a live Australian market, repeat orders and enough excess capacity that could be used to increase profit margins as reasons why the Community author believes this biotech is currently undervalued.
PMV Pharmaceuticals (PMVP)
Overview: PMV Pharmaceuticals is a Princeton-based biotech developing small molecule therapies aimed at correcting p53 mutations, led by rezatapopt in Phase 2 trials.
Market Cap: $102.7 million
PMV Pharmaceuticals fits into this fast-growing, below book value biotech screen because its p53-focused rezatapopt program targets a specific mutation with Phase 2 data already reported. The stock trades around 1.5x P/B while the company remains loss-making and reliant on funding. This leaves much dependent on how one future inflection in that program affects the balance between risk and reward.
That hinge point is exactly what the 1 key reward and 3 important warning signs (2 are major!) unpacks so you can see where PMV Pharmaceuticals’ risk could be masking upside.
NanoViricides (NNVC)
Overview: NanoViricides is a clinical-stage biopharmaceutical developer creating nanoengineered antiviral drugs. Its NV-387 respiratory virus candidates are central to its potential.
Market Cap: $23.9 million
NanoViricides fits this biotech screen because NV-387 and its NV-CoV-2 oral and injectable formats target large, recurring respiratory virus markets, while the stock trades below many peers on P/B despite no revenue yet. Investors are essentially pricing expectations around how a combination of funding developments and trial outcomes may affect demand projections for this antiviral platform.
To see how those funding and trial scenarios are currently being priced into NanoViricides, review the analysis report for NanoViricides to understand where expectations could be misaligned with the underlying science.
Seeking Fresh Alternatives Before They Fly
Markets move fast and early information edge fades quickly. Fresh breakout setups, cooling momentum, and dropping valuations rarely stay under the radar for long, so getting in early can be important.
Spot under-the-radar strength and rotate into cash-generative compounders using the curated 33 high-quality undervalued stocks before renewed interest reduces the window for mispriced quality.
Track capital flowing into real-world infrastructure and position around long-term electrification themes through the focused 38 power grid technology and infrastructure stocks while it still flies below the crowd’s radar.
Target cash-producing miners geared to potential metal price swings with the refined 36 elite gold producer stocks to seek opportunities before any late-stage momentum.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Andrew Legget and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.